Trial reportVeterinary dermatology2014
Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
Trial report in Veterinary dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 63 citations in OpenAlex.
- Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.Veterinary dermatology · 2016Trial
- A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.Veterinary dermatology · 2015Trial
- Hydrocortisone Aceponate for Chronic Otitis: Long-Term Efficacy.Veterinary dermatology · 2025Article
- Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial.Veterinary dermatology · 2025Article
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025Review
- Immunotherapy using pullulan-conjugated Der f 2 allergen in canine atopic dermatitis: An anti-inflammatory agent-sparing approach.Veterinary dermatology · 2025Article
- Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats.The Canadian veterinary journal = La revue veterinaire canadienne · 2025Article
- Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs.Journal of veterinary pharmacology and therapeutics · 2025Review
- Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis.Veterinary dermatology · 2025Article
- Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies.Veterinary medicine (Auckland, N.Z.) · 2024Review
- Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib.Frontiers in veterinary science · 2023Article
- The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study.BMC veterinary research · 2022Article
- Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs.Veterinary sciences · 2022Review
- A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.Veterinary dermatology · 2021Article
- The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study.Frontiers in veterinary science · 2021Article
- Serum canine thymus and activation-regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis.Veterinary dermatology · 2020Article
- Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.BMC veterinary research · 2019Article
- A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.BMC veterinary research · 2019Article
- STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.Journal of veterinary internal medicine · 2018Article
- JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.Journal of veterinary internal medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral glucocorticoids are widely used to reduce pruritus and dermatitis associated with allergic dermatitis. Data suggest that oclacitinib, a Janus kinase inhibitor, is a safe and effective alternative. HYPOTHESIS/
objectivesTo evaluate the efficacy and safety of oclacitinib compared with prednisolone for the control of pruritus associated with allergic dermatitis in a single-masked, controlled clinical trial with a randomized complete block design. ANIMALS: Client-owned dogs (n = 123) with a presumptive diagnosis of allergic dermatitis and moderate to severe pruritus as assessed by the pet owner were enrolled.
methodsDogs were randomized to treatment with either oclacitinib (0.4-0.6 mg/kg orally twice daily for 14 days, then once daily) or prednisolone (0.5-1.0 mg/kg once daily for 6 days, then every other day) for 28 days. An enhanced visual analog scale (VAS) was used by owners to assess pruritus and by veterinarians to assess dermatitis, at all time points assessed.
resultsBoth treatments produced a rapid onset of efficacy within 4 h. The mean reductions in pruritus and dermatitis scores were not significantly different between the treatments except on day 14, when reductions were more pronounced for oclacitinib than prednisolone (P = 0.0193 for owner pruritus scores; P = 0.0252 for veterinarian dermatitis scores). Adverse events were reported with similar frequency in both groups. CONCLUSION AND CLINICAL IMPORTANCE: In this study, both oclacitinib and prednisolone provided rapid, effective and safe control of pruritus associated with allergic dermatitis, with substantial improvement in pruritus, reported by owners, and dermatitis, reported by veterinarians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.